Hiccups treatment
Reading File
Finding Sources
Searching PubMed
hiccups treatment management
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
hiccups treatment guidelines 2024 2025 persistent intractable
Here is a structured overview of hiccups treatment, drawing on textbook sources and current evidence:
Hiccups (Singultus) - Treatment
Classification by Duration
| Type | Duration | Clinical Relevance |
|---|---|---|
| Acute/Benign | <48 hours | Usually self-limiting; no underlying pathology |
| Persistent | 48 hrs - 1 month | Often has identifiable cause |
| Intractable | >1 month | Requires thorough investigation and pharmacotherapy |
Step 1 - Treat the Underlying Cause
This is the most successful approach for persistent/intractable hiccups. Common surgical/medical causes include:
- Postoperative - dilated stomach or paralytic ileus causing upward pressure on the diaphragm. Treatment: insert a nasogastric tube and aspirate to decompress the stomach. Pethidine (meperidine) or chlorpromazine may be added if needed.
- Peritonitis - involving the diaphragmatic peritoneum causing repeated hiccup
- Advanced renal failure - check for uraemic signs (dry brown tongue), investigate urgently
- Steroid-induced - reducing the corticosteroid dose usually resolves hiccups
- CNS lesions - brainstem infarcts, posterior fossa tumors, fourth-ventricle pressure
- GI causes - gastroesophageal reflux, gastric distension
(S Das Manual on Clinical Surgery, p. 20; Plum & Posner's Diagnosis and Treatment of Stupor and Coma, p. 122)
Step 2 - Non-Pharmacological Measures (Acute Hiccups)
These work by stimulating the vagus nerve or raising CO2 to interrupt the reflex arc:
- Breath-holding or rebreathing into a paper bag (raises PaCO2)
- Drinking cold water rapidly or swallowing sugar/ice
- Applying pressure to the eyeballs (Valsalva-type vagal stimulation)
- Nasopharyngeal stimulation (e.g., cotton-tipped applicator to soft palate)
- Tongue traction
- Startling the patient
- Controlled phrenic nerve stimulation via transcutaneous electrical means (used in hospital settings)
These maneuvers work well for benign episodic hiccups but have limited success in pathological cases.
Step 3 - Pharmacological Treatment
Used when hiccups are persistent/intractable or have a central/neurological cause. Evidence base is limited (no high-quality RCTs), but current guidance (Steger et al. systematic review) recommends:
First-Line Agents
| Drug | Dose | Mechanism |
|---|---|---|
| Baclofen | 5-10 mg TID | GABA-B agonist; reduces excitability of the hiccup reflex arc |
| Gabapentin | 300-400 mg TID | Calcium channel modulation; anticonvulsant |
| Pregabalin | 75-150 mg BD | Same mechanism as gabapentin |
These are preferred over neuroleptics for long-term use due to a lower adverse effect profile.
Second-Line / Reserve Agents
| Drug | Notes |
|---|---|
| Chlorpromazine (phenothiazine) | Only FDA-approved drug for hiccups; sedating; use short-term |
| Metoclopramide | Dopamine antagonist; useful if gastric cause suspected |
| Haloperidol | Useful in palliative/end-of-life settings |
| Nifedipine | Calcium channel blocker; some evidence for persistent hiccups |
(Plum & Posner, p. 122; Medscape Hiccups Treatment; systematic review data via ResearchGate 2024)
Special Populations
- Palliative care / cancer patients: Hiccups are common with chemotherapy and corticosteroids. Haloperidol and metoclopramide are frequently used. A 2025 systematic review (PMID: 40055925) specifically addresses perioperative hiccups management.
- Postoperative patients: Nasogastric decompression is first step; pethidine or chlorpromazine if needed.
- Neurological patients (brainstem lesion + tracheostomy): Hiccup-driven ventilation can actually maintain respiration - exercise caution before suppressing hiccups.
Key Clinical Takeaway
Pathologic hiccups are difficult to treat. No single drug is clearly superior. Baclofen and gabapentin are the current preferred first-line pharmacological options for persistent/intractable hiccups due to their favorable safety profile. Chlorpromazine remains the only FDA-approved drug but is reserved for short-term or second-line use. Always investigate and treat the underlying cause first.
Recent evidence note: The 2025 systematic review on perioperative hiccups (PMID 40055925) is the most current high-quality evidence available; it reinforces the pharmacological framework above. A 2024 systematic review with treatment algorithm proposes baclofen as the recommended first-line agent.
Phenargan injection
Reading File
Finding Sources
Searching the Web
Phenergan promethazine injection uses dose side effects 2024
Reading File
Reading File
Reading Web Page
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48186…
Finding Sources
Reading File
Here is a complete clinical reference for Phenergan (Promethazine) Injection:
Phenergan (Promethazine HCl) Injection
Drug Profile
| Property | Details |
|---|---|
| Generic name | Promethazine hydrochloride |
| Brand name | Phenergan |
| Drug class | First-generation phenothiazine antihistamine |
| Mechanism | H1 receptor antagonist (primary); weak D2 antagonism; anticholinergic; CNS depressant |
| Available strengths | 25 mg/mL and 50 mg/mL solution for injection |
| Routes | Deep IM (preferred), IV (with caution) - NOT subcutaneous or intra-arterial |
Indications
- Allergic conditions - urticaria, angioedema, anaphylaxis adjunct, allergic rhinitis
- Nausea and vomiting - motion sickness, postoperative nausea, general antiemesis
- Sedation / pre-operative sedation - procedural sedation, adjunct to analgesia
- Rapid tranquilisation (psychiatry) - 50 mg IM for agitated/benzodiazepine-tolerant patients
- Motion sickness prophylaxis
- Adjunct to opioid analgesia - potentiates analgesic effect, reduces required opioid dose
Dosage
| Indication | Adult Dose | Notes |
|---|---|---|
| Nausea/vomiting (antiemetic) | 12.5-25 mg IM or IV every 4 hours | Start at 12.5 mg; repeat in 30 min if needed |
| Sedation / pre-op | 25-50 mg IM | Combined with reduced dose of opioid |
| Allergy/urticaria | 25 mg IM, repeat in 2 hrs if needed | |
| Rapid tranquilisation | 50 mg IM | Option in benzodiazepine-tolerant patients |
| Motion sickness | 25 mg IM | Given 30-60 min before travel |
Paediatric (2 years and older): Use the lowest effective dose. Avoid in children under 2 years (fatal respiratory depression risk).
Geriatric: Reduce dose; elderly are more sensitive to sedation, hypotension, and anticholinergic effects.
IV Administration (if used): Dilute in 10-20 mL of 0.9% NaCl and administer slowly over 10-15 minutes. Confirm IV patency before injection. Deep IM is strongly preferred.
(Rosen's Emergency Medicine, Table 25.7; DailyMed FDA label)
Mechanism of Antiemetic Action
Acts primarily at the H1 receptor in the chemoreceptor trigger zone (CTZ), with minimal D2 receptor activity. This differentiates it from dopamine antagonist antiemetics (metoclopramide, prochlorperazine). Its strong anticholinergic activity also contributes to antiemesis and sedation.
Black Box Warnings
1. Severe Tissue Injury / Gangrene
- Injection can cause severe chemical irritation regardless of route
- Intra-arterial injection causes gangrene - absolutely contraindicated
- Subcutaneous injection causes tissue necrosis - absolutely contraindicated
- Extravasation risk with IV: causes burning, pain, thrombophlebitis, tissue necrosis, paralysis
- Deep IM injection is the preferred route for this reason
2. Respiratory Depression (Paediatric)
- Contraindicated in children under 2 years - risk of fatal respiratory depression
- Use lowest effective dose in children 2 years and older
- Avoid combining with other CNS/respiratory depressants in children
Contraindications
- Children under 2 years of age
- Intra-arterial injection
- Subcutaneous injection
- Comatose states
- Known hypersensitivity to promethazine or other phenothiazines
- Angle-closure glaucoma (relative)
- Bladder neck obstruction (relative)
- Lower respiratory tract disease (asthma, COPD) - relative
Side Effects
| System | Effect |
|---|---|
| CNS | Sedation (most common), dizziness, disorientation, extrapyramidal reactions |
| Anticholinergic | Dry mouth, urinary retention, constipation, blurred vision, tachycardia |
| Cardiovascular | Hypotension, QT prolongation (less than other phenothiazines) |
| Local (injection site) | Burning, pain, erythema, tissue necrosis if extravasation |
| Respiratory | Respiratory depression (especially in children and with CNS depressants) |
| Haematological | Leukopenia, agranulocytosis (rare) |
| Other | Photosensitivity, neuroleptic malignant syndrome (rare) |
Drug Interactions
- CNS depressants (alcohol, opioids, benzodiazepines, barbiturates, anaesthetics): potentiation of sedation and respiratory depression - reduce doses of both agents
- Tricyclic antidepressants: additive anticholinergic and CNS depression
- MAOIs: potentially severe interactions
- Anticholinergic agents: additive effects
- Haloperidol + promethazine IM: common combination in rapid tranquilisation - do not mix in the same syringe
Special Clinical Uses
Rapid Tranquilisation (Psychiatry)
Promethazine 50 mg IM is a validated option for acutely agitated patients, particularly those with benzodiazepine tolerance. It is used in combination with haloperidol (but in separate syringes) for very agitated patients. Evidence from the TREC trials supports the haloperidol + promethazine combination. (Maudsley Prescribing Guidelines, 15th ed.)
Antiemetic Stepwise Protocol (Emergency Medicine)
Promethazine sits after ondansetron, metoclopramide, and droperidol/haloperidol in the stepwise antiemetic algorithm. It is useful when sedation is also desired. (Rosen's Emergency Medicine)
Key Practical Points
- Always use deep IM injection - never subcutaneous
- If IV route is necessary, dilute and inject slowly (over 10-15 min); confirm IV is patent
- Do not combine with dimenhydrinate (additive sedation)
- Reduce dose in elderly and patients on other sedating drugs
- Can potentiate opioid analgesia, allowing dose reduction of opioid
- Strong anticholinergic profile - avoid in BPSD (dementia-related behavioural problems) due to risk of cognitive impairment (Maudsley Guidelines)
This is a shared conversation. Sign in to Orris to start your own chat.